Withdrawal-Induced Delirium in Opioid Dependence: A Systematic Review

TL;DR

This review examines delirium caused by opioid withdrawal, highlighting its rarity, diagnostic challenges, and the need for better understanding and treatment strategies.

Contribution

The paper systematically reviews case reports to characterize delirium in opioid withdrawal and proposes future research directions.

Findings

Delirium occurred within hours to days of opioid withdrawal onset, with symptoms like disorientation and perceptual disturbances.

Risk factors included psychiatric comorbidities, psychotropic medications, rapid detox, and adulterated substances.

Management strategies varied but included benzodiazepines, antipsychotics, and opioid agonist reinstatement.

Abstract

Background: Delirium is a rare but clinically significant complication of opioid withdrawal that remains poorly characterized in the literature. While classical withdrawal symptoms are well recognized, atypical presentations such as delirium are less frequently reported and often challenging to diagnose due to symptom overlap and heterogeneity of withdrawal syndromes. Methods: In this systematic review, we systematically analyzed available case reports and case series describing delirium precipitated by spontaneous opioid withdrawal, tapering, or antagonist-induced withdrawal. Twelve papers met inclusion criteria, comprising a total of fifteen case reports. Results: Most patients (n = 15) developed delirium within hours to days of withdrawal onset, often with fluctuating consciousness, disorientation, perceptual disturbances, and psychomotor changes. Reported risk factors included psychiatric comorbidity (major depressive disorder, anxiety disorder), concomitant use of psychotropic medication, rapid detoxification protocols, and potential exposure to adulterated substances. Management strategies varied but generally involved supportive care, benzodiazepines, antipsychotics, or reinstatement of opioid agonists. Conclusions: The findings highlight the need for heightened clinical awareness, careful differentiation from other withdrawal-related neuropsychiatric states, and systematic exclusion of organic etiologies. Despite the increasing number of patients affected by OWS, the knowledge available to date is based on case reports and a small case series, making it impossible to critically assess the prevalence or identify risk factors. Future research should aim to identify risk factors, optimize treatment, and explore novel diagnostic approaches, including AI-driven monitoring and connectomic analyses, to improve early detection and therapeutic outcomes in opioid withdrawal-associated delirium.

Figures